Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

New Therapies for HNSCC

August 10th 2017

Refining Chemoradiation for Advanced HNSCC

August 10th 2017

The Role of Induction Chemotherapy in HNSCC

August 10th 2017

Surgery for Locally Advanced HNSCC

August 10th 2017

De-Escalation of Therapy for HPV-Positive HNSCC

August 10th 2017

Personalized Approaches to Head and Neck Cancer Therapy

August 10th 2017

Head and Neck Cancer and the AJCC 8th Edition

August 10th 2017

Genetic Landscape of HNSCC

August 10th 2017

Biology of Head and Neck Cancer

August 10th 2017

Dr. Weiss on Developments in the Treatment of Head and Neck Cancer

August 10th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses developments of immunotherapy trials for patients with head and neck cancer.

Dr. Cohen on Challenges with Immunotherapy in Head and Neck Cancer

August 9th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses challenges with immunotherapy in head and neck cancer.

Expert Highlights Avelumab Trial and Future of Immunotherapy in Head and Neck Cancer

August 8th 2017

Nancy Y. Lee, MD, discusses the ongoing JAVELIN HEAD AND NECK 100 trial and the overall impact of immunotherapy for patients with head and neck cancer.

Dr. Burtness on Challenges Facing Immunotherapy in Head and Neck

August 7th 2017

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses challenges regarding immunotherapy for patients with head and neck cancer.

Dr. Bauml Discusses Immunotherapy Agents in Head and Neck Cancer

August 3rd 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy agents in head and neck cancer.

Dr. Weiss on the Role of Immunotherapy in Head and Neck Cancer

August 3rd 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the role of immunotherapy in head and neck cancer.

Erlotinib Linked to Improved Survival in HNSCC

July 30th 2017

Results showed that adding erlotinib to cisplatin and docetaxel was superior to chemotherapy alone for both overall survival and progression-free survival in head and neck squamous cell carcinoma.

Dr. Cohen on Immunotherapy in Head and Neck Squamous Cell Carcinoma

July 27th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy in head and neck squamous cell carcinoma.

Dr. Bauml on CAR T-Cell Therapy in Head and Neck Cancer

July 27th 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses CAR T-cell therapy in head and neck cancer.

Dr. Burtness on Immunotherapy Resistance in Head and Neck Cancer

July 27th 2017

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses immunotherapy resistance in head and neck cancer.

FDA Accepts sBLAs for 4-week Nivolumab Dosing Schedule

July 26th 2017

The FDA has accepted supplemental Biologics License Applications seeking to add a second dosing schedule for nivolumab (Opdivo) across all of the PD-1 inhibitor’s monotherapy indications.